Literature DB >> 15247811

Preplacement nerve testing for carpal tunnel syndrome: is it cost effective?

Alfred Franzblau1, Robert A Werner, Joanne Yihan.   

Abstract

UNLABELLED: Is not hiring otherwise-qualified workers who have an abnormal post-offer preplacement (POPP) median nerve test a cost-effective strategy to reduce workers' compensation expenses related to carpal tunnel syndrome (CTS)? We performed a retrospective dynamic cohort study based on 2150 workers hired at a company between January 1996 and December 2001 and who underwent POPP median nerve testing. Workers were followed until they left the company or until follow-up ended in May 2003.
RESULTS: Thirty-five cases of work-related CTS occurred during follow-up, and 9.13 cases could have been avoided. However, if the company had not hired workers with abnormal POPP nerve test results, it would have suffered a net loss of $357,353.
CONCLUSION: Not hiring workers with abnormal POPP nerve tests to reduce costs of work-related CTS is not a cost-effective strategy for employers.

Entities:  

Mesh:

Year:  2004        PMID: 15247811     DOI: 10.1097/01.jom.0000131798.48162.63

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  10 in total

1.  Physical examination has a low yield in screening for carpal tunnel syndrome.

Authors:  Ann Marie Dale; Alexis Descatha; Justin Coomes; Alfred Franzblau; Bradley Evanoff
Journal:  Am J Ind Med       Date:  2010-10-28       Impact factor: 2.214

2.  Postoffer Pre-Placement Screening for Carpal Tunnel Syndrome in Newly Hired Manufacturing Workers.

Authors:  Ann Marie Dale; Bethany T Gardner; Skye Buckner-Petty; Jaime R Strickland; Bradley Evanoff
Journal:  J Occup Environ Med       Date:  2016-12       Impact factor: 2.162

Review 3.  Evaluation of work-related carpal tunnel syndrome.

Authors:  Robert A Werner
Journal:  J Occup Rehabil       Date:  2006-06

4.  Modeling the cost-benefit of nerve conduction studies in pre-employment screening for carpal tunnel syndrome.

Authors:  Bradley Evanoff; Steve Kymes
Journal:  Scand J Work Environ Health       Date:  2010-05-25       Impact factor: 5.024

5.  Comparison of automated versus traditional nerve conduction study methods for median nerve testing in a general worker population.

Authors:  Ann Marie Dale; Folasade Agboola; Amber Yun; Angelique Zeringue; Muhammed T Al-Lozi; Bradley Evanoff
Journal:  PM R       Date:  2014-10-15       Impact factor: 2.298

6.  The effectiveness of post-offer pre-placement nerve conduction screening for carpal tunnel syndrome.

Authors:  Ann Marie Dale; Bethany T Gardner; Angelique Zeringue; Robert Werner; Alfred Franzblau; Bradley Evanoff
Journal:  J Occup Environ Med       Date:  2014-08       Impact factor: 2.162

Review 7.  Pre-employment examinations for preventing injury, disease and sick leave in workers.

Authors:  Frederieke G Schaafsma; Norashikin Mahmud; Michiel F Reneman; Jean-Baptiste Fassier; Franciscus H W Jungbauer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-12

Review 8.  Economic evaluations of occupational health interventions from a company's perspective: a systematic review of methods to estimate the cost of health-related productivity loss.

Authors:  Kimi Uegaki; Martine C de Bruijne; Allard J van der Beek; Willem van Mechelen; Maurits W van Tulder
Journal:  J Occup Rehabil       Date:  2011-03

9.  Reducing Disability Durations and Medical Costs for Patients With a Carpal Tunnel Release Surgery Through the Use of Opioid Prescribing Guidelines.

Authors:  Fraser W Gaspar; Roman Kownacki; Catherine S Zaidel; Craig F Conlon; Kurt T Hegmann
Journal:  J Occup Environ Med       Date:  2017-12       Impact factor: 2.162

10.  Movements of the wrist and the risk of carpal tunnel syndrome: a nationwide cohort study using objective exposure measurements.

Authors:  Christina Bach Lund; Sigurd Mikkelsen; Lau Caspar Thygesen; Gert-Åke Hansson; Jane Frølund Thomsen
Journal:  Occup Environ Med       Date:  2019-06-12       Impact factor: 4.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.